carbidopa levodopa

Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson’s disease

Nature.com - 05 Nov 2024
Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson’s disease ...

Carbidopa/Levodopa Formulations & Parkinson's Disease | APDA

American Parkinson Disease Association - 08 Oct 2024
Carbidopa/Levodopa Formulations & Parkinson's Disease | APDA ...

FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s

Medscape - 18 Oct 2024
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s ...

New Extended-Release Parkinson's Drug Approved

Medpage Today - 08 Aug 2024
New Extended-Release Parkinson's Drug Approved ...

3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev

FiercePharma - 17 Oct 2024
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev ...

FDA approves Vyalev for advanced Parkinson's disease

Medical Xpress - 23 Oct 2024
FDA approves Vyalev for advanced Parkinson's disease ...

FDA approves new Parkinson’s treatment based on clinical trial led by USF Health faculty

University of South Florida - 08 Aug 2024
FDA approves new Parkinson’s treatment based on clinical trial led by USF Health faculty ...

Avion Pharmaceutical's, LLC, Dhivy® (carbidopa/levodopa) and Parkinson's disease advocate, American Ninja Warrior, Jimmy Choi to participate at Rock Steady Boxing Coach Con Myrtle Beach

PR Newswire - 03 Oct 2024
Avion Pharmaceutical's, LLC, Dhivy® (carbidopa/levodopa) and Parkinson's disease advocate, American Ninja Warrior, Jimmy Choi to participate at Rock Steady Boxing Coach Con Myrtle Beach ...

FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's

Yahoo Finance - 18 Oct 2024
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's ...

FDA approves extended-release levodopa/carbidopa, now Crexont

Parkinson's News Today - 08 Aug 2024
FDA approves extended-release levodopa/carbidopa, now Crexont ...

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT

Business Wire - 07 Aug 2024
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT ...

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

The Lancet - 15 Mar 2024
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial ...

AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease

MarketWatch - 17 Oct 2024
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease ...

U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease

StockTitan - 17 Oct 2024
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease ...

Crexont®: A Newly Approved Parkinson’s Medication

American Parkinson Disease Association - 08 Aug 2024
Crexont®: A Newly Approved Parkinson’s Medication ...

Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson’s disease patients

Nature.com - 14 Feb 2024
Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson’s disease patients ...